BioNTech Target of Unusually High Options Trading (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX - Get Free Report) saw unusually large options trading on Tuesday. Investors bought 4,599 call options on the company. This represents an increase of approximately 58% compared to the average daily volume of 2,906 call options.

Institutional Trading of BioNTech

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Planning Capital Management Corp boosted its holdings in BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company's stock worth $54,000 after buying an additional 450 shares during the last quarter. Blue Trust Inc. boosted its stake in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock worth $55,000 after acquiring an additional 388 shares during the last quarter. GAMMA Investing LLC grew its holdings in BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company's stock valued at $74,000 after purchasing an additional 111 shares during the period. Daiwa Securities Group Inc. increased its stake in BioNTech by 430.3% in the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company's stock valued at $155,000 after purchasing an additional 1,562 shares in the last quarter. Finally, Caprock Group LLC acquired a new stake in BioNTech in the second quarter worth $206,000. 15.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on BNTX shares. TD Cowen cut their target price on BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research note on Tuesday, November 5th. Morgan Stanley upgraded shares of BioNTech from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Canaccord Genuity Group upped their target price on shares of BioNTech from $171.00 to $171.44 and gave the company a "buy" rating in a research note on Wednesday, November 27th. UBS Group raised their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a "neutral" rating in a research note on Wednesday, September 18th. Finally, HSBC lifted their price objective on BioNTech from $97.00 to $136.00 and gave the company a "buy" rating in a report on Monday, October 7th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and a consensus target price of $140.76.

BioNTech Price Performance

Shares of BNTX stock traded up $6.67 during trading hours on Tuesday, reaching $126.88. 2,013,664 shares of the company were exchanged, compared to its average volume of 908,322. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a market cap of $30.42 billion, a price-to-earnings ratio of -60.42 and a beta of 0.18. The stock's fifty day moving average is $113.72 and its two-hundred day moving average is $102.79. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $514.08 million. During the same period last year, the firm earned $0.73 EPS. The business's revenue for the quarter was up 38.9% on a year-over-year basis. Sell-side analysts forecast that BioNTech will post -3.72 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.